CCR5 antagonists: Host-targeted antiviral agents for the treatment of HIV infection, 4 years on

Antiviral Chemistry and Chemotherapy

Volumn 20, Issue 5, 2010, Pages 179-192

  Westby, Mike ^a   Van Der Ryst, Elna ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; APLAVIROC; ATAZANAVIR PLUS RITONAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INCB 9471; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PF 232798; PRO 140; RITONAVIR; TBR 652; UNCLASSIFIED DRUG; VICRIVIROC;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT FAILURE; VIRUS LOAD;

EID: 77951157311     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/imp1507     Document Type: Review

References (117)

1. Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005; 16:339-354. (Pubitemid 41746045)
2. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008; 52:858-865. (Pubitemid 351358363)
3. Yeni P, Lamarca A, Berger D, et al. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naive patients: results of the EPIC study (CCR100136). HIV Med 2009; 10:116-124.
4. Currier J, Lazzarin A, Sloan L, et al. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Antivir Ther 2008; 13:297-306. (Pubitemid 351535381)
5. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15:241-243.
6. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49:4911-4919. (Pubitemid 41782160)
7. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008; 198:1113-1122.
8. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007; 196:304-312. (Pubitemid 47047471)
9. Keung A, Prasad P, Martinho M, et al. A pharmacokinetic-pharmacodynamic (PK-PD) disease model to describe short- and long-term antiviral activity of vicriviroc (VCV). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. 27-30 September 2006, San Francisco, CA, USA. Abstract A-0387.
10. Gulick R, Haas D, Collier AC, Lennox J, Parker C, Greaves W. Two-year follow-up of treatment-experienced patients on vicriviroc (VCV). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, USA. Abstract H-1030.
11. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-1455.
12. Gulick R, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
13. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine/lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1. J Infect Dis 2010; 201:803-813.
14. Heera J, Ive P, Botes M, et al. The MERIT study of maraviroc in antiretroviral-naive patients with R5 HIV-1: 96-week results. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract TUAB103.
15. Dorr P, Westby M, McFadyen L, et al. PF-232798, a second generation oral CCR5 antagonist. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, USA. Abstract 737.
16. Erickson-Viitanen S, Ambremski K, Solomon K, et al. Co-receptor tropism, ENV genotype, and in vitro susceptibility to CCR5 antagonists during a 14-day monotherapy study with INCB9471. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, USA. Abstract 862.
17. Jacobson JM, Saag MS, Thompson MA, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008; 198:1345-1352.
18. Thompson M, Lalezari J, Saag M, et al. Weekly and biweekly subcutaneous PRO 140 demonstrates potent, sustained antiviral activity. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, Canada. Abstract 571a.
19. Pugach P, Ketas TJ, Michael E, Moore JP. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 2008; 377:401-407.
20. Palleja S, Driz R, Wang-Smith L, et al. Pharmacokinetics (PK), safety, and tolerability of single doses of the chemokine C-C rceptor 5 (CCR5) antagonist TBR-652 in healthy volunteers. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract WEPEB251.
21. Suleiman J, Zingman BS, Diaz RS, et al. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J Infect Dis 2010; 201:590-599.
22. McCarthy MC, Suleiman J, Diaz R, et al. Vicriviroc long-term safety and efficacy: 96-week results from the VICTOR-E1 Study. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September 12-15 2009, San Francisco, USA. Abstract H-923.
23. Boucher C, Schapiro JM, Kuritzkes D, et al. Genotypic and phenotypic weighted optimized background therapy susceptibility scores are similarly strong predictors of virologic response <50 copies/mL at Week 48 in MOTIVATE 1 and 2. Antivir Ther 2009; 14 Suppl 1:A52.
24. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. (Pubitemid 46541620)
25. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
26. Saag M, Goodrich J, Fätkenheuer G, et al. A double-blind, placebo controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199:1638-1647.
27. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857): a potent, orally bioavailable and selective small-molecule inhibitor of the chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732. (Pubitemid 41552605)
28. + T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2009; doi: 10.1097/QAI. 0b013e3181c5c83b.
29. + cell increases at 48 weeks in the maraviroc treatment-naive MERIT trial. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. 26-28 October 2008, Washington, DC, USA. Abstract H-1248.
30. Nelson M, Fisher M, Gonzalez-Garcia J, et al. Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus an optimized background therapy (OBT) versus placebo plus OBT in the MOTIVATE 1 and 2 trials. XVII International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract TUPE0119.
31. Wilkin T, Ribaudo H, Gulick R. The relationship of CCR5 inhibitors to CD4 cell count changes: a meta-analysis of recent clinical trials. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, USA. Abstract 800.
32. Neaton JD, Lane HC. Getting personal about treating HIV. Nat Med 2008; 14:369-370.
33. LaBonte JA, Madani N, Sodroski J. Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression. J Virol 2003; 77:6645-6659. (Pubitemid 36666858)
34. + T cells contributes to the extent of human immunodeficiency virus type 1 viral replication-mediated T cell death. AIDS Res Hum Retroviruses 2004; 20:1230-1243.
35. Decrion AZ, Dichamp I, Varin A, Herbein G. HIV and inflammation. Curr HIV Res 2005; 3:243-259.
36. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
37. Telenti A. Safety concerns about CCR5 as an antiviral target. Curr Opin HIV AIDS 2009; 4:131-135.
38. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197:262-265. (Pubitemid 351263445)
39. Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:266-269. (Pubitemid 351263446)
40. Singh H, Sachan R, Jain M, Mittal B. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res 2008; 17:87-91. (Pubitemid 351796815)
41. Srivastava A, Pandey SN, Choudhuri G, Mittal B. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility. Scand J Immunol 2008; 67:516-522. (Pubitemid 351519396)
42. Ugurel S, Schrama D, Keller G, et al. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother 2008; 57:685-691. (Pubitemid 351641030)
43. Balistreri CR, Carruba G, Calabro M, et al. CCR5 proinflammatory allele in prostate cancer risk: a pilot study in patients and centenarians from Sicily. Ann N Y Acad Sci 2009; 1155:289-292.
44. Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH, Watanabe MA. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 2009; 23:429-435.
45. Petersen DC, Severi G, Hoang HN, et al. No association between common chemokine and chemokine receptor gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17:3615-3617.
46. Ajuebor MN, Aspinall AI, Zhou F, et al. Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells. J Immunol 2005; 174:8027-8037. (Pubitemid 40806314)
47. Moreno C, Gustot T, Nicaise C, et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 2005; 42:854-862. (Pubitemid 41401123)
48. Ayoub A, Goodrich J, van der Ryst E, Heera J, Mayer H. Adverse event profile of maraviroc in treatmentexperienced patients infected with R5 HIV-1. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. 25-28 October 2008, Washington, DC, USA. Abstract H-1264.
49. Hoepelman IM, Ayoub A, Heera J, et al. The incidence of severe liver enzyme abnormalities and hepatic adverse events in the maraviroc clinical development programme. 11th European AIDS Conference. 24-27 October 2007, Madrid, Spain. Abstract LBP7.9/1.
50. Hardy WD, Gulick R, Mayer H, et al. Efficacy and safety of maraviroc in treatment-experienced patients infected with R5 HIV-1: 96-week combined analysis of the MOTIVATE 1 and 2 studies. Ninth International Congress on Drug Therapy in HIV Infection. 9-13 November 2008, Glasgow, UK. Abstract O425.
51. Dunkle L, Greaves W, McCarthy M, et al. Long-term safety of vicriviroc. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. 25-28 October 2008, Washington DC, USA. Abstract H-1269.
52. Tsibris AM, Paredes R, Chadburn A, et al. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis 2009; 48:642-649.
53. Ayoub A, Walmsley S, Campo R, et al. Incidence and risk factors for malignancies in treatment-experienced (TE) patients in the MOTIVATE studies of maraviroc (MVC) + optimized background therapy (OBT): 96-week follow-up. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract WEPEB255.
54. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58:19-42. (Pubitemid 33070762)
55. Ogert RA, Wojcik L, Buontempo C, et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008; 373:387-399.
56. Westby M. Resistance to CCR5 antagonists. Curr Opin HIV AIDS 2007; 2:137-144.
57. Moore JP, Kuritzkes DR. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 2009; 4:118-124.
58. Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF. Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope. Antimicrob Agents Chemother 2009; 53:1124-1131.
59. Mori J, Lewis M, Simpson P, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2 (24 week analysis). 6th European HIV Drug Resistance Workshop. 26-28 March 2008, Budapest, Hungary. Abstract 51.
60. Mori J, Mosley M, Lewis M, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2. Antivir Ther 2007; 12:S12.
61. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 2002; 99:395-400. (Pubitemid 34060372)
62. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-2371. (Pubitemid 46303353)
63. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, Kuhmann SE. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361:212-228. (Pubitemid 46551222)
64. Buontempo C, Ogert R, Ba L, et al. Effect of virus concentration on in vitro measurement of phenotypic resistance to the CCR5 antagonist vicriviroc. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, USA. Abstract 863.
65. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005; 67:1268-1282. (Pubitemid 40410427)
66. Seibert C, Ying W, Gavrilov S, et al. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 2006; 349:41-54.
67. Maeda K, Das D, Ogata-Aoki H, et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 2006; 281:12688-12698. (Pubitemid 43855359)
68. Nishikawa M, Takashima K, Nishi T, et al. Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob Agents Chemother 2005; 49:4708-4715. (Pubitemid 41552603)
69. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008; 73:789-800. (Pubitemid 351397884)
70. Heera J, Saag M, Ive P, et al. Virological correlates associated with treatment failure at week 48 in the Phase 3 study of maraviroc in treatment-naive patients. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, USA. Abstract 40LB.
71. Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM. Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob Agents Chemother 2009; 53:1116-1123.
72. Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A 2009; 106:5318-5323.
73. Lewis M, Mori J, Simpson P, et al. Changes in V3 loop sequence associated with failure of maraviroc (MVC) treatment in patients enrolled in the MOTIVATE 1 and 2 trials. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, USA. Abstract 871.
74. Marozsan AJ, Kuhmann SE, Morgan T, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005; 338:182-199. (Pubitemid 40835936)
75. Kuhmann SE, Pugach P, Kunstman KJ, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78:2790-2807. (Pubitemid 38314338)
76. Tsibris A, Leopold K, Paredes R, et al. Reduced fitness of vicriviroc-resistant HIV-1 leads to rapid post-treatment reversion in vivo. 16th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2009, Montreal, Canada. Abstract 638.
77. Yoshimura K, Harada S, Hatada M, Matsushita S. Mutations in V4 and C4 regions of the HIV-1 CRF08-BC envelope induced by the in vitro selection of maraviroc confer cross-resistance to other CCR5 inhibitors. 16th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2009, Montreal, Canada. Abstract 640.
78. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-474. (Pubitemid 41023125)
79. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.
80. de Roda Husman AM, Schuitemaker H. Chemokine receptors and the clinical course of HIV-1 infection. Trends Microbiol 1998; 6:244-249. (Pubitemid 28288154)
81. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21:265-304.
82. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169:968-974. (Pubitemid 24303213)
83. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46:1617-1623. (Pubitemid 351706746)
84. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004; 17:7-16. (Pubitemid 39089967)
85. Huang W, Coakley E, Toma J, et al. Transitions from CCR5 to CXCR4 use in the absence of antiretroviral drug pressure proceed incrementally and may occur through a multitude of genetic pathways. XVIII International HIV Drug Resistance Workshop. 9-13 June 2009, Fort Myers, USA. Abstract 13.
86. Däumer MP, Kaiser R, Klein R, Lengauer T, Thiele BT, Thielen A. Inferring viral tropism from genotype with massively parallel sequencing: qualitative and quantitative analysis. Antivir Ther 2008; 13 Suppl 3:A101.
87. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the Phase 3 studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus. Antivir Ther 2007; 12:S65.
88. van der Ryst E, Westby M. Changes in HIV-1 co-receptor tropism for patients participating in the maraviroc MOTIVATE 1 and 2 clinical trials. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, USA. Abstract H-715.
89. Huang W, Eshleman SH, Toma J, et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007; 81:7885-7893. (Pubitemid 47101474)
90. Lewis M, Simpson P, Li X, Robertson DL, Whitcomb J, Westby M. Dual-tropic virus clones from patients enrolled in the MOTIVATE studies may respond differently in vivo to maraviroc based on their V3 loop sequence. 6th European HIV Drug Resistance Workshop. 26-28 March 2008, Budapest, Hungary. Abstract 50.
91. Perno CF, Andreonil M, Svicher V, et al. Phenotypic analysis and deep sequencing show a preferential usage of CCR5 or CXCR4 receptor among dual-tropic, HIV primary isolates. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, Canada. Abstract 434.
92. Irlbeck DM, Amrine-Madsen H, Kitrinos KM, LaBranche CC, Demarest JF. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS 2008; 22:1425-1431.
93. Swenson L, Dong W, Mo T, et al. Quantification of HIV tropism by "deep" sequencing shows a broad distribution of prevalence of X4 variants in clinical samples that is associated with virological outcome. 16th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2009, Montreal, Canada. Abstract 680.
94. Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, USA. Abstract 790.
95. Johnson M, Campbell T, Clotet B, et al. DUET-2: Week-48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, USA. Abstract 791.
96. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-475. (Pubitemid 44142769)
97. Cooper D, Gatell J, Rockstroh J, et al. 48-week results from BENCHMRK-1, a Phase III study of raltegravir in patients failing antiretroviral therapy with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, USA. Abstract 788.
98. Steigbigel R, Kumar P, Eron J, et al. 48-week results from BENCHMRK-2, a Phase III study of raltegravir in patients failing antiretroviral therapy with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, USA. Abstract 789.
99. Fätkenheuer G, Hoffmann C, Slim J, et al. A randomized, double-blind, placebo-controlled study of adding vicriviroc to ART in patients with hepatitis C co-infection. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, USA. Abstract 510.
100. Thio CL, Astemborski J, Bashirova A, et al. Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol 2007; 81:441-445. (Pubitemid 46067870)
101. Thio CL, Astemborski J, Thomas R, et al. Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. J Immunol 2008; 181:7944-7947.
102. Bruno R, Galastri S, Sacchi P, et al. The HIV envelope protein gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 2009; doi:10.1136/gut.2008.163287.
103. Seki E, De Minicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 2009; 119:1858-1870.
104. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569. (Pubitemid 32709592)
105. Benhamou Y, Bochet M, Di MV, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058. (Pubitemid 29458296)
106. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-872. (Pubitemid 40349800)
107. Demarest J, Bonny T, Vavro C, et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October-2 November 2004, Washington, DC, USA. Abstract H-1136.
108. Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJ, Moore JP. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 2005; 11:1293-1294. (Pubitemid 41752908)
109. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438:99-102. (Pubitemid 41599827)
110. Mechai F, Quertainmont Y, Sahali S, Delfraissy JF, Ghosn J. Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person. J Med Virol 2008; 80:9-10. (Pubitemid 350220083)
111. Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:546-553.
112. Fletcher PS, Herrera C, Armanasco N, et al. Anti-HIV activity of the candidate microbicide maraviroc, a CCR5 receptor antagonist. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract WEPDC201.
113. Low AJ, Swenson LC, Harrigan PR. HIV coreceptor phenotyping in the clinical setting. AIDS Rev 2008; 10:143-151.
114. Harrigan PR, McGovern R, Dong W, et al. Screening for HIV tropism using population-based V3 genotypic analysis: a retrospective virological outcome analysis using stored plasma screening samples from MOTIVATE-1. Antivir Ther 2009; 14 Suppl 1:A17.
115. Strang AL, Camerin J, Booth C, Garcia A, Geretti AM. Genotypic prediction of viral co-receptor tropism: correlation with enhanced Trofile. 7th European HIV Drug Resistance Workshop. 25-27 March 2009, Stockholm, Sweden. Abstract 80.
116. Swenson LC, McGovern RA, Dong W, et al. Optimization of clinically relevant cutoffs for determining HIV co-receptor use by population and 'deep' sequencing methods. 47th Annual Meeting of the Infectious Diseases Society of America. 29 Oct-1 Nov 2009, Philadelphia, PA, USA. Abstract 279.
117. Gathe J, Diaz R, Fatkenheuer G et al. Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 54LB.